💉 COVID-19 Vaccine Adverse Events (2020-2025): VAERS Real-World Surveillance Data This dataset offers a critical, large-scale look into the real-world safety surveillance of COVID-19 vaccines, sourced from the Vaccine Adverse Event Reporting System (VAERS). Maintained by the CDC and FDA, this collection spans the unprecedented period of mass vaccination from 2020 through 2025, providing an invaluable resource for pharmacovigilance, public health research, and regulatory decision-making.

Key Features & Challenge The dataset is a rich blend of structured and unstructured information detailing reported Adverse Drug Events (ADEs), which range from mild local reactions to severe, life-threatening complications.

Structured Data: Includes standardized symptom codes, offering a direct, quantitative view of reported reactions.

Free-Text Notes: Contains verbose, real-world symptom descriptions provided by reporters. This text is a "treasure trove" of granular context, including details on duration, intensity, and location of symptoms.

The Challenge: The structured entries are limited in scope. The free-text notes, while rich, are inherently noisy and lack standardized metadata such as clinical severity scores or age-specific pattern normalization.

Value to Data Scientists This dataset presents a significant Natural Language Processing (NLP) and Machine Learning (ML) challenge:

Extracting Context: Develop models to effectively extract critical clinical context (e.g., "headache lasting three days, severe") from the raw, non-standardized free-text notes.

Standardizing Severity: Create predictive models to assign standardized severity and age-specific risk patterns to ADEs.

Informed Decision Making: The ultimate goal is to generate actionable, timely insights for regulators, healthcare providers, and pharmaceutical companies, improving both vaccine safety monitoring and public trust.

Dive into this dataset to apply your skills in advanced data cleaning, feature engineering, and state-of-the-art NLP to solve a crucial, high-impact public health challenge.

The coronavirus pandemic has affected the entire world and many families have been destroyed. The stock exchange was also affected, but vaccine companies took advantage of this moment and leveraged their profits

Biotech companies:

• PFIZER: Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas.

• ASTRAZENECA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• BIONTECH: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

• MODERNA: Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

• NOVAVAX: Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.

Check the movement of the financial market through this dataset

Use your creativity and external information

COVID-19 Reopening Data from Associated Press and Kantar Media

Access regularly updated data from The Associated Press and Kantar Media containing information on events at the global, national and state levels as economies reopen following the coronavirus pandemic via AP Planner.

AP Planner is a paid service from The Associated Press & Kantar Media.

The four data files below feature the following event types:

• Environmental, Social and Governance (ESG): Events related the factors that measure the sustainability and societal impact of an investment in a company or business.
• Healthcare, Pharmaceuticals and Bio Tech: Health care providers and services, health care equipment and supplies, and health care technology companies. Drug and vaccine production, as well as biological substances for the purposes of drug discovery and diagnostic development.
• Politics: U.S. political news and events.
• Diversity and Discrimination: News and events related to race, religion, gender, sexuality, disability and age.

All data is compiled by a dedicated staff with over 15 years of forward planning research experience, employing data verification and processes designed to provide reliable and up-to-date information.

The data can be used to help:

• Provide signals to investors on how to act and at what speed based on the types of events returning across industries.
• Analyze risk associated with companies based on when they're reopening.
• Retain your own customer base based on reopening dates for vendors and competitors.
• Track COVID regulations to prepare inventory and guest policies.

The following data files are samples - if you are interested in licensing the full, regularly updated database, please contact Opal Barclay (obarclay@ap.org) at The Associated Press or Click on Request Access Button above.

​

***

FAQs

Why does AP and Kantar compile this data?_ The data is sourced from AP Planner, a product offered by The Associated Press and Kantar Media. AP Planner is a searchable database of future events that is updated daily and intended for research, not publication.

What information does AP Planner contain?_ AP Planner is global in scope and contains more than 100,000 U.S. and international events from the world of news, current affairs, politics, business, lifestyle and more - all searchable up to 12 months ahead.

Where does the information come from?_ AP Planner aggregates listings from tens of thousands of organizations worldwide. Our research staff monitors over 350,000 websites and uses a verity of secondary sources including press releases, corporate announcements and other outlets to ensure accuracy.

How can I be confident of the data's quality and accuracy?_ We have a dedicated research staff with over 15 years of forward planning research experience. They employ data verification and updating processes designed to provide our customers with completely reliable and up-to-date information.

Can I export data into other applications?_ Yes, AP Planner data can be exported as an Excel file or an Outlook calendar file. The data is also accessible via API.

Who can I contact to learn more about AP Planner?_ Opal Barclay, obarclay@ap.org.

When a company decides it would like to sell a drug or vaccine in Canada, it files a submission with Health Canada. A new drug submission contains detailed scientific information about the drug's safety, efficacy and quality. Health Canada scientific reviewers evaluate data to assess the potential benefits and risks of a drug or vaccine. They also review the information that will be provided to health care practitioners and consumers about the product. After the review, we may authorize the drug or vaccine for sale in Canada only if the benefits of the product outweigh the potential risks.

Free-Cash-Flow-To-The-Firm Time Series for Moderna Inc. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The file contains 9,921 tweets labelled with the concerns towards vaccines. There are 3 columns in the file: - ID of the tweet in a string format, appended with a "t" (to make it easier to work with on spreadsheet softwares). - The tweet text - The different labels (vaccine concerns) expressed in the tweet, seperated by spaces.

List of the 12 different vaccine concerns in the dataset: - [unnecessary]: The tweet indicates vaccines are unnecessary, or that alternate cures are better. - [mandatory]: Against mandatory vaccination — The tweet suggests that vaccines should not be made mandatory. - [pharma]: Against Big Pharma — The tweet indicates that the Big Pharmaceutical companies are just trying to earn money, or the tweet is against such companies in general because of their history. - [conspiracy]: Deeper Conspiracy — The tweet suggests some deeper conspiracy, and not just that the Big Pharma want to make money (e.g., vaccines are being used to track people, COVID is a hoax) - [political]: Political side of vaccines — The tweet expresses concerns that the governments / politicians are pushing their own agenda though the vaccines. - [country]: Country of origin — The tweet is against some vaccine because of the country where it was developed / manufactured - [rushed]: Untested / Rushed Process — The tweet expresses concerns that the vaccines have not been tested properly or that the published data is not accurate. - [ingredients]: Vaccine Ingredients / technology — The tweet expresses concerns about the ingredients present in the vaccines (eg. fetal cells, chemicals) or the technology used (e.g., mRNA vaccines can change your DNA) - [side-effect]: Side Effects / Deaths — The tweet expresses concerns about the side effects of the vaccines, including deaths caused. - [ineffective]: Vaccine is ineffective — The tweet expresses concerns that the vaccines are not effective enough and are useless. - [religious]: Religious Reasons — The tweet is against vaccines because of religious reasons - [none]: No specific reason stated in the tweet, or some reason other than the given ones.

Stock Price Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.

BackgroundCoronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant loss of life and property. In response to the serious pandemic, recently developed vaccines against SARS-CoV-2 have been administrated to the public. Nevertheless, the research on human immunization response against COVID-19 vaccines is insufficient. Although much information associated with vaccine efficacy, safety and immunogenicity has been reported by pharmaceutical companies based on laboratory studies and clinical trials, vaccine evaluation needs to be extended further to better understand the effect of COVID-19 vaccines on human beings.MethodsWe performed a comparative peptidome analysis on serum samples from 95 participants collected at four time points before and after receiving CoronaVac. The collected serum samples were analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to profile the serum peptides, and also subjected to humoral and cellular immune response analyses to obtain typical immunogenicity information.ResultsSignificant difference in serum peptidome profiles by MALDI-TOF MS was observed after vaccination. By supervised statistical analysis, a total of 13 serum MALDI-TOF MS feature peaks were obtained on day 28 and day 42 of vaccination. The feature peaks were identified as component C1q receptor, CD59 glycoprotein, mannose-binding protein C, platelet basic protein, CD99 antigen, Leucine-rich alpha-2-glycoprotein, integral membrane protein 2B, platelet factor 4 and hemoglobin subunits. Combining with immunogenicity analysis, the study provided evidence for the humoral and cellular immune responses activated by CoronaVac. Furthermore, we found that it is possible to distinguish neutralizing antibody (NAbs)-positive from NAbs-negative individuals after complete vaccination using the serum peptidome profiles by MALDI-TOF MS together with machine learning methods, including random forest (RF), partial least squares-discriminant analysis (PLS-DA), linear support vector machine (SVM) and logistic regression (LR).ConclusionsThe study shows the promise of MALDI-TOF MS-based serum peptidome analysis for the assessment of immune responses activated by COVID-19 vaccination, and discovered a panel of serum peptides biomarkers for COVID-19 vaccination and for NAbs generation. The method developed in this study can help not only in the development of new vaccines, but also in the post-marketing evaluation of developed vaccines.

Dividends-Paid Time Series for Shanghai Fosun Pharmaceutical Group Co Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for oncology and immunomodulation, metabolism and digestive system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetologym personal care, dentistry, injection filling, respiratory health, mobile pre-hospital care, professional in-hospital surgery, and surgical robots and medical consumables for pre-hospital emergency, neurosurgery, orthopedics, and oncology fields; and solutions for biochemical, immune, molecular, microbiological, and pathological diagnosis, as well as chronic care management. In addition, the company offers online and offline medical services, such as pharmaceuticals and medical devices, consumer healthcare and healthcare commodities, and other comprehensive commodities; specialized medical treatment; and insurance services. The company was founded in 1994 and is based in Shanghai, China.

Barriers to COVID-19 vaccination from semi-structured interviews (n = 29).

Income-Before-Tax Time Series for Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells vitro diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccine. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests, as well as support services. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates as a subsidiary of Yangshengtang Co., Ltd.

Total-Current-Liabilities Time Series for Shanghai Fosun Pharmaceutical Group Co Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for oncology and immunomodulation, metabolism and digestive system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetologym personal care, dentistry, injection filling, respiratory health, mobile pre-hospital care, professional in-hospital surgery, and surgical robots and medical consumables for pre-hospital emergency, neurosurgery, orthopedics, and oncology fields; and solutions for biochemical, immune, molecular, microbiological, and pathological diagnosis, as well as chronic care management. In addition, the company offers online and offline medical services, such as pharmaceuticals and medical devices, consumer healthcare and healthcare commodities, and other comprehensive commodities; specialized medical treatment; and insurance services. The company was founded in 1994 and is based in Shanghai, China.

Association between demographics and subjects’ perception, vaccine acceptance, and misinformation (n = 484).

Change-To-Inventory Time Series for Moderna Inc. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Knowledge of COVID-19 and COVID-19 vaccine among participants (n = 377).

Depreciation Time Series for Moderna Inc. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sample interview questions by topics.

Socio-demographic characteristics and distribution of COVID-19 vaccine acceptance (n = 377).

Cash-and-Short-Term-Investments Time Series for Shanghai Fosun Pharmaceutical Group Co Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory health and professional medical products; oncology, neuroscience and other specialty fields; and solutions for infections, tumors, the central nervous system, and chronic diseases. In addition, the company offers online and offline medical services, such as pharmaceuticals and medical devices, consumer healthcare and special commodities; specialized medical disciplines; and insurance services. Further, it is involved in the import and export of medical equipment and the provision of related and other consulting services and investment management. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Factors associated with COVID-19 vaccine acceptance among participants.